Cullinan Therapeutics, Inc.
CGEM
$12.69
-$0.44-3.35%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -6.43% | -24.78% | -66.69% | -30.56% | -100.17% |
| Total Depreciation and Amortization | 2.60% | 3.95% | 0.00% | 0.00% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 4.21% | 80.08% | 20.17% | 49.36% | 167.96% |
| Change in Net Operating Assets | 27.44% | 201.03% | 464.81% | 69.63% | 45.65% |
| Cash from Operations | -4.05% | -8.02% | -58.74% | -12.83% | -102.01% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 40.33% | 239.22% | 128.85% | 184.08% | -68.98% |
| Cash from Investing | 40.26% | 239.03% | 128.85% | 184.08% | -68.98% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -54.80% | -100.00% | -99.86% | -- | 537.90% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -54.80% | -100.00% | -99.86% | -- | 537.90% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 21.37% | 335.89% | -109.40% | 73.77% | -156.81% |